February 15, 2019 / 6:51 AM / 2 months ago

BRIEF-Immunovia Q4 Pretax Loss Widens To SEK 25.7 Mln

Feb 15 (Reuters) - Immunovia AB:

* REPORTED ON THURSDAY Q4 NET SALES SEK 91,000 VS SEK 26,000 YR AGO

* Q4 PRETAX LOSS SEK 25.7 MLN VS LOSS SEK 15.3 MLN YR AGO

* CO’S FINANCIAL TARGETS REMAIN IN PLACE FROM THE PREVIOUS QUARTER

* EXPECTS TO RECEIVE THE FIRST REVENUES FROM SELF-PAY SALES IN THE LATTER PART OF 2019

* TARGET IS TO ACHIEVE TURNOVER OF SEK 250-300 MILLION BY 2022 BASED ON SELF-PAY FOR IMMRAY PANCAN–D

* TARGET IS TO ACHIEVE TOTAL TURNOVER, INCLUDING PAYMENT VIA SELF-PAY AND COST REMUNERATION FROM INSURANCE SYSTEMS, OF SEK 800-1,000 MILLION BY 2024

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below